ArticleBMC pediatrics2026
Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in risk-adapted chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT), relapse remains the leading cause of treatment failure and mortality in pediatric acute lymphoblastic leukemia (ALL). Achieving measurable residual disease (MRD)-negative status prior to allo-HSCT is strongly associated with improved outcomes. This study aimed to compare the effectiveness of blinatumomab versus conventional re-induction chemotherapy in relapsed/refractory pediatric B cell acute lymphoblastic leukemia (B-ALL) patients.
methodThis retrospective, non-randomized cohort study included pediatric patients (1-18 years) diagnosed with relapsed/refractory CD19⁺ B-ALL. Patients received either conventional re-induction chemotherapy followed by consolidation according to institutional protocols or blinatumomab administered as a continuous intravenous infusion in 28-day cycles. Treatment allocation was based on physician decision and drug availability. Primary endpoints included complete remission (CR) and MRD negativity after one treatment cycle. Secondary endpoints included eligibility for allo-HSCT, relapse-free survival, overall survival, and adverse events.
resultsA total of 52 patients were analyzed (blinatumomab, n = 30; chemotherapy, n = 22). MRD negativity after one cycle was significantly higher in the blinatumomab group compared with chemotherapy (83.4% vs. 18.2%, P < 0.001). A greater proportion of patients in the blinatumomab group proceeded to allo-HSCT (68.2% vs. 40%, P = 0.041). Overall survival was significantly improved with blinatumomab (77.3% vs. 30%, P < 0.001). Mortality was primarily associated with FAB type L3 following the first treatment cycle.
conclusionsIn this retrospective cohort of pediatric patients with relapsed/refractory B-ALL, blinatumomab was associated with significantly higher MRD negativity rates, improved transplant eligibility, and superior survival compared with conventional chemotherapy. These findings support the role of blinatumomab as an effective therapeutic option in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.